Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy
SC GM atrophy is detectable in patients with 5q-SMA and is consistently associated with clinical measures of upper limb function, physiotherapeutic assessments, and SMA-FRS indicating the clinical relevance of the observed atrophy. Further longitudinal investigations are necessary next steps to evaluate this novel and easily applicable imaging marker as a potential disease course and therapeutic response marker.
Authors
- Claudia Weidensteiner (ORCID: https://orcid.org/0009-0007-8272-3817)
- Tanja Haas (ORCID: https://orcid.org/0000-0003-3287-3378)
- Eva Kesenheimer (ORCID: https://orcid.org/0000-0003-3566-8628)
- Nathalie Braun (ORCID: https://orcid.org/0000-0002-1734-0023)
- Christoph Neuwirth (ORCID: https://orcid.org/0000-0002-1874-8872)
- Matthias Weigel (ORCID: https://orcid.org/0000-0002-4910-1414)
- Regina Schlaeger (ORCID: https://orcid.org/0000-0003-2056-5765)
- Maria Janina Wendebourg (ORCID: https://orcid.org/0000-0003-4812-8807)
- Oliver Bieri (ORCID: https://orcid.org/0000-0002-6755-5495)
- Laura Sander (ORCID: https://orcid.org/0000-0002-9191-4005)
- Dirk Fischer (ORCID: https://orcid.org/0000-0002-0792-6370)
- Cristina Granziera (ORCID: https://orcid.org/0000-0002-4917-8761)
- Michael Sinnreich (ORCID: https://orcid.org/0000-0002-9835-1276)
- Markus Weber (ORCID: https://orcid.org/0000-0002-5538-9274)
Institutions
- University of Basel (CH)
- Kantonsspital St. Gallen (CH)
- University Hospital of Basel (CH)
- Swiss Paraplegic Center (CH)
- University Children’s Hospital Basel (CH)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1007/s00415-024-12740-3
- Citations
- 2
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Sanofi
- Biogen
- Universität Basel
- Argenx
- Mitsubishi Tanabe Pharma Corporation
- Sanofi Genzyme